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Summary Amifostine (WR-2721), a thiol compound, has been shown to protect normal tissue from
alkylating agents and cisplatin-induced toxicity without loss of anti-tumour effects. To confirm this result, we
conducted a phase II randomised trial to determine if the addition of amifostine reduces the toxicity of
carboplatin without loss of anti-tumour activity in patients with inoperable non-small-cell lung cancer
(NSCLC). After the first course of carboplatin (600 mg m2 i.v. infusion), 21 patients were randomised to
receive three cycles of carboplatin alone (C arm) or three infusions of amifostine at 910 mg m 2 (CA arm) at
28 day intervals. The amifostine was given 20min before and at 2 and 4 h after carboplatin. Since the
910 mgm2 amifostine infusion led to hypotension in six patients, the dosage was reduced by 25%, to
683 mg m-2 t.i.d., in the other four patients. Amifostine was well tolerated at this dose level. Five patients in
the CA arm and three in the C arm had their planned treatment discontinued owing to progressive disease
(n = 3), amifostine side-effects (hypotension, sneezing and sickness, n = 4), and carboplatin-induced throm-
bocytopenia (n = 1). Bone marrow and renal function at study entry and after the first course of carboplatin
before randomisation were similar in both treatment arms. Twenty courses of carboplatin + amifostine have
been compared with 25 courses of carboplatin alone. Although there was no statistically significant difference
with respect to haematological values comparing both arms, the median time to platelet recovery
(>100 x 109 1-l) (13.5 days vs 21 days; P = 0.04) and the need for hospitalisation for i.v. antibiotic and other
supportive treatment tended to be reduced in the CA arm (0/20 vs 6/25 patient courses; P = 0.06). Response
rates and median survival (14 vs 9 months) were no different, excluding tumour protection activity by
amifostine. These results with a small number of patients suggest that amifostine given with carboplatin may
reduce the duration of thrombocytopenia and hospitalisation.
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Amifostine (Ethyol), previously referred to as WR-2721, is an
organic thiophosphate which was developed by the US army
during the cold war as a radioprotective agent (McCulloch et
al., 1991; Capizzi et al., 1993). In animal models, it also
protects normal tissue against the toxicity of cytotoxic agents
such as platinum and alkylating compounds (Yuhas et al.,
1980; Patchen et al., 1992; van der Wilt et al., 1992; van Laar
et al., 1992; Treskes et al., 1994; van der Vijgh et al., 1994).
Amifostine is a prodrug that is dephosphorylated to its active
metabolite, a free thiol, by alkaline phosphatase at the tissue
site. Coupled with the fact that normal tissue concentrates
the free thiol metabolite, it is immediately available to bind
and detoxify alkylating and platinum agents (Treskes et al.,
1991; van der Vijgh et al., 1994). The administration of
amifostine together with chemotherapy suggests that it might
have value in protecting patients from myelosuppression
(Glover et al., 1986; Glick et al., 1992; Budd et al., 1993;
Capizzi, 1994; Poplin et al., 1994) and, in the case of
cisplatinum-containing schedules, from neurotoxicity and
nephrotoxicity (Mollman et al., 1988; Glick et al., 1992).
Carboplatin as a single agent therapy has been shown to
have activity in non-small-cell lung cancer (NSCLC) with
response rates from 8% to 20% in four trials testing carbo-
platin 400 mg m-2 as a single dose or fractionated over 3
days (Bonomi, 1991). In a recent phase I dose-escalating
study in patients with lung tumour, carboplatin was
administered in a dosage of 800, 1200 and 1600 mg m-2
(Smith, 1992). The major toxicity noted was myelosuppres-
sion, and nephropathy, neuropathy, severe nausea and
vomiting were rare. To investigate the extent of bone marrow
protection by amifostine in patients with NSCLC on
treatment with single dose carboplatin, we performed a ran-
domised phase II trial. The extent and duration of myelosup-
pression, the incidence of infection and the use of antibiotics
were the primary parameters of the study.
Patients and methods
Patient selection
The patients enrolled in this trial had to meet all the follow-
ing criteria: histologically proven NSCLC, inoperability, age
18 to 70 years, performance status < 2 (Eastern Cooperative
Oncology Group scale), measurable and/or evaluable lesions,
no prior cytotoxic treatment, absence of other malignancies,
no hypertension requiring therapy other than diuretics and a
life expectancy greater than 2 months. An adequate bone
marrow reserve (white blood count (WBC) >4 x I0' -1;
platelet > 100 x I091'), adequate liver function (AST, ALT
and bilirubin <2 x upper limit of normal range), and ade-
quate renal function (serum creatinine< 1.25 x upper limit
of normal range; creatinine clearance>65 ml min- ) were
also required. In the case of previous major surgery, the
patient had to have fully recovered. This study was carried
out with the approval of the South Manchester ethics com-
mittee, and all patients accepted into this study signed an
informed consent statement in accordance with the Food and
Drug Administration guidelines and The Declaration of Hel-
sinki.
Treatmentplan
Four weeks after a first course of carboplatin (600 mgm-2,
30 min i.v infusion) as a single agent, eligible patients were
randomised to receive three further courses of carboplatin
(600 mg m-2 i.v.) with or without amifostine 910 mg m-2
t.i.d. Because of the amifostine toxicity in six patients, in
particular hypotension, the dose was reduced to 683 mgm-2
i.v. t.i.d. (75% of the scheduled dose). Amifostine was given
20 min before and at 2 and 4 h after each carboplatin course
as a 15Xnin i.v. infusion. Three courses were planned at 4
weekly intervals, if the creatinine clearance was >65 ml
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min-' and if the following haematological criteria were met:
WBC> 3 x 109 1-l, platelet>100 x I0 I-'. Platelet and/or
red blood cell transfusions were given in the case of throm-
bocytopenia (<20 x 1091') and/or anaemia (<95 gI`).
Drugs, which would have affected bone marrow function
and/or blood cell count (e.g. steroids) and blood pressure
(e.g. phenothiazine), were not prescribed.
Response assessment
Pretreatment evaluation included a medical history, physical
examination, full blood count, biochemical profile, chest
radiograph, computerised tomography (CT) scan and any
other diagnostic procedure appropriate to assess the extent of
the disease. Blood counts were performed weekly. Physical
examination and biochemical profile were carried out accord-
ing to WHO criteria every two courses (World Health
Organization, 1979).
Toxicity
Side-effects were reported according to the standard WHO
criteria. If patients developed fever in association with neut-
ropenia and/or platelet count <20 x 109 1-l (in the case of
bleeding <50 x 1091-) the subsequent carboplatin dose
could be reduced by 25%. All patients treated with amifos-
tine had their blood pressure measured immediately before
and every 5 min during the amifostine infusion until 5 min
after the infusion was completed. If the systolic blood pres-
sure dropped more than 20% from the baseline value or if
the patient developed symptoms related to decreased cerebral
perfusion, the infusion of amifostine was interrupted. As
soon as the patient had recovered (absence of symptoms,
blood pressure above the threshold value within Smin of
stopping the infusion), the amifostine treatment was re-
started. In the case of prolonged blood pressure drop, all
subsequent doses of amifostine were reduced by 20%.
Statistical analysis
Log-rank, Wilcoxon rank sum and Fisher's exact tests were
used for comparing the haematological values, the occurrence
of infections, the need for transfusions and antibiotics and
times to platelet, WBC and neutrophil recovery within each
treatment arm and between the two arms. The worst nadir
blood counts taken from the weekly counts were used for
analysis. A Kaplan-Meier analysis was used to assess the
median time to platelet/blood transfusion for each treatment
arm and survival.
Results
Patient characteristics
A total of 21 patients were enrolled in this randomised study.
Their clinical characteristics are summarised in Table I. One
patient declined the amifostine treatment after randomisation
(CA arm) and was therefore followed up only for response
and survival. Major prognostic factors were well balanced
between both arms and measurements of the renal function
(serum creatinine and creatinine clearance) as well as the
blood cell counts revealed no statistically significant differ-
ence before randomisation.
Treatment and toxicity (Table II)
Five of the ten patients in the carboplatin/amifostine arm
(CA arm) and seven of the ten patients in the carboplatin
alone arm (C arm) received all four courses according to the
protocol. Five patients who received amifostine at a dose of
910 mgm2 t.i.d. had their treatment interrupted because of
amifostine toxicity (hypotension, sickness, retching and
sneezing). One of these patients was removed from the study
owing to severe hypotension accompanied by bifascicular
Table I Patient characteristics
Carboplatin/amifostine Carboplatin alone
Sex
Male 8 8
Female 3 2
Age
Median 64 61
Range 45-69 41-70
ECOG performance status
0 2 1
1 7 5
2 2 4
Histology
Squamous 5 7
Adenocarcinoma 5 2
Large cell 1 1
Stage
III B 8 5
IV 3 5a
Courses
Course 1 11 10
Courses 2-4 20 25
aOne patient with lung metastases had undergone pneumonectomy
before chemotherapy.
block, which was present before treatment. In three patients
(one in the CA arm and two in the C arm), the
chemotherapy was suspended because of progressive disease,
and in one patient (C arm) treatment was interrupted
because of thrombocytopenia and cerebral haemorrhage. The
most common side-effects associated with amifostine were
nausea and vomiting (90%) despite antiemetic therapy with
ondansetron (Table II). Flushing, episodic sneezing and diz-
ziness were reported in five, three and two patients respec-
tively, and hypotension occurred in 15 of 20 patient courses
(75%). The latter was the most important event and led in 15
courses to an interruption of the amifostine infusion. In 12
courses the amifostine infusion could be restarted, in three
patients, however, no further infusion was given for the
course as the hypotension lasted for longer than 5 min after
interruption of the infusion. The carboplatin dose as assessed
by calculation of the area under the curve (AUC) (Calvert et
al., 1989) did not indicate any difference between both arms
for courses 1 and 2. However, the AUC was 7% greater in
the CA arm for courses 3 and 4 (P = 0.03), owing to a
carboplatin dose reduction in one patient in the C arm
because of grade IV thrombocytopenia.
Efficacy ofamifostine
After the first course of carboplatin the haematological
values were similar in both arms (Table III). This control
indicated that the bone marrow function before amifostine
was similar in both patient populations. Haemoglobin,
leucocyte, neutrophil and platelet counts on courses 2-4
showed no statistically significant advantage for the amifos-
tine arm. The median nadir was similar in both arms. In
addition, the incidence ofgrade 3 or 4 thrombocytopenia and
neutropenia was not statistically different between the two
treatment arms. However, the time to platelet recovery
(>100 x 1091-') after carboplatin was reduced in the CA
arm (13.5 days vs 21 days, P = 0.04) (Table III). No statis-
tically significant differences were seen between the two arms
with respect to the time to total WBC and neutrophil
recovery. The platelet transfusion requirement was similar in
both arms: an average of 5.6 unitscourse-' and 5.7 units
course-1 of platelets were transfused in the CA arm and C
arm respectively. Red blood cell transfusions were given as
an average of 2.6 units course-' in both arms. However, one
patient in the C arm had his carboplatin dose reduced owing
to grade 4 thrombocytopenia and another patient, also in the
C arm, had his treatment interrupted because of haemor-
rhage with severe thrombocytopenia. In contrast, no patientCarboplatin and amifostine in lung cancer
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Table III Haemoglobin, neutrophil and platelet nadir and time to
platelet recovery (>100 x 1091-). Median and range of all patient
courses are shown
Carboplatin + amifostine Carboplatin
Course 1
Hb (gl-') 107 (77-136) 98 (78-133)
Neutrophil (x 1091-l) 1.2 (0.3-13.3) 1.4 (0.2-21.7)
Platelet (x 1091-1) 26(14-870) 34(9-749)
Recovery time (days) 8 (7-13) 11.5 (9-14)
Courses 2-4
Hb (gl-') 82 (69-96) 83 (71-152)
Neutrophil (x 1091-1) 0.9 (0.3-15.6) 1.2 (0.1-30.7)
Platelet (x 1091-') 21 (8-515) 23 (2-269)
Recovery time (days) 13.5 (8-17) 21.0 (20-26)
in the CA arm had the carboplatin dose reduced or discon-
tinued owing to pancytopenia.
Although there was no statistically significant difference in
the infection incidence comparing both treatment groups (10/
25 and 3/20 for C and CA respectively), patients in the C
arm tended to be hospitalised more frequently mainly for i.v.
antibiotics and other supportive treatment (6/25 vs 0/20
patient courses, P = 0.06).
Tumour response and survival
The response rate was evaluable in 19 patients (in two
patients, one in each arm, tumour size was not assessable
owing to lung atelectasis); seven patients had a partial res-
ponse, five in the CA arm (5/10), and two in the C arm (2/9).
Four patients in the CA arm and one patient in the C arm
who responded had limited disease. The median survival was
14 months and 9 months in the CA and C groups respec-
tively.
Discussion
Amifostine is a thiol compound that is thought to protect
normal bone marrow against the toxic effects of chemo-
therapy while not diminishing the antineoplastic efficacy of
the cytotoxic agent (Gandara et al., 1990, 1991; McCulloch
et al., 1991; Schuchter et al., 1992; Capizzi et al., 1993, 1994;
Treskes et al., 1993). Recently published studies have shown
a lessening of pancytopenia and/or a shortened time to
recovery for neutrophils and platelets if amifostine was given
with chemotherapy (Glover et al., 1986; Glick et al., 1992,
1994; Budd et al., 1993; Poplin et al., 1994). These therapies
included agents such as cyclophosphamide (Glover et al.,
1986; Glick et al., 1994), cisplatinum (Glover et al., 1987;
Mollman et al., 1988; Glick et al., 1992, 1994; Schiller et al.,
1994), mitomycin (Poplin et al., 1994) and vinblastine (Poplin
et al., 1994). In addition, a reduction in infections requiring
antibiotics and days in hospital has been reported in a large
randomised phase III study of patients with ovarian cancer
treated with cisplatinum and cyclophosphamide (Glick et al.,
1994). A possible protection of amifostine with carboplatin
has been recently suggested in a phase I investigation (Budd
et al., 1993).
Pharmacokinetic studies in phase I clinical trials revealed
that amifostine is cleared from the plasma within 6min of
the completion of a 15 min infusion (half-life time T 1/2: a
0.9 min and 9 min) (Shaw et al., 1986). These phar-
macokinetic data, therefore, are important in planning
clinical protection trials and support the rationale for
repeated amifostine administration particularly when used
with carboplatin for which the half-life is relatively long (a;
30-60min and ,B; 450-1200min) (Van Echo et al., 1989).
In the present randomised phase II study, we investigated
the haematological toxicity after monotherapy with carbo-
platin for inoperable NSCLC. The predominant haematolog-
.s.)
0 N
E0
0
0 8-
a)o
0
a)
a)*E
E ,'.
*_)
a)
C'.E
E0
0, ,
E
oo
E0 Z
. C.
z 0
0C X
XC-
-0 _
_ 0%
00
mI or--- r-a-,-
__
I'0o
00
_N
Oq R O
-a_ t_
00
00
ON
-
'.0.
No
~O II
0% 0
O .I ,
_ N
_
0o1 t 00£
000
_OC
oot U
a
C)
0 a)
a
0
.- 0
c)
._
0
a
a)
a
,
C-
.0
'0
cO
c)
a)
r.
.0
C)
la a)
CO
'U
O
0
0
coi
A
a)
v
CO
0
a
CO
C)4
.0
00
00
I.0
0
'0 8
a w
w
*0
O
w
E1
bo
E
en
'0 r
co
en
2o
=1
a
10 C)
'0
CO Q.
0% v) aCarboplatin and amifostine in lung cancer
_M DC Betticher etal
1 5F4A
ical toxicity associated with carboplatin is thrombocytopenia
(Canetta et al., 1985). Although the severity of throm-
bocytopenia was not influenced by amifostine, the time to
recovery appeared to be shortened compared with patients
treated with carboplatin alone (P = 0.04) (Table III). The
need for hospitalisation for i.v. antibiotic and other suppor-
tive treatment tended to be less in the amifostine group
(P = 0.06). Although the neutrophil nadir count and time to
recovery were similar, perhaps because of the analysis having
been performed on the worst counts rather than the median
values of the weekly counts, no other statistically significant
differences were seen and the need for transfusions were
similar in both patient arms. The results could also be due to
the cumulative nature of carboplatin's haematological tox-
icity and a possible 'carry over' effect from the first course of
carboplatin.
Although renal and bone marrow function were well
balanced between both groups, the carboplatin AUC as back
calculated from the dose given and creatinine clearances
(Calvert et al., 1989) was significantly greater (7%) in the CA
arm on courses 3-4. This difference is due, at least to some
extent, to dose reduction of carboplatin in one patient in the
C arm. This finding strengthens the results with respect to
amifostine effect on platelet recovery duration and incidence
of severe infection.
Amifostine led to important side-effects such as hypoten-
sion, malaise, retching and sneezing at a dose level of
910mg m2 t.i.d. Subsequent doses, therefore, were reduced
by 25% to 683 mgm-2 t.i.d. At this dose level, amifostine
was well tolerated and, as in other studies, nausea, vomiting,
flushing, episodic sneezing, dizziness and hypotension were
mild to moderate in intensity. No hypocalcaemia observed
previously (Wadler et al., 1993; O'Rourke et al., 1994) was
noticed and there was no evidence of cumulative toxicity
from the three daily doses of amifostine.
Studies in animal models suggest an increased response
rate when amifostine is administered. In mice with ovarian
carcinoma xenografts (Treskes et al., 1994) amifostine
administered before carboplatin had a potentiating effect on
tumour growth inhibition. In a randomised trial in patients
with ovarian cancer (Glick et al., 1992) complete responses
and survival with a median follow-up of 40 months were
similar. In the present study the number of patients is too
small to allow any conclusion on response. Nevertheless, the
response and survival data like the study performed in
ovarian cancer (Glick et al., 1992) argues against any tumour
protection by amifostine.
Taken together, no activity of amifostine on the blood cell
nadir, transfusions, time to recovery of neutrophils and
haemoglobin could be observed in the present study.
Therefore, it was considered unreasonable to recruit addi-
tional patients onto this study. However, amifostine given
with carboplatin appears to shorten the duration of
carboplatin-induced thrombocytopenia and tends to reduce
hospitalisation with fewer infections necessitating the use of
i.v. antibiotics and less supportive care. Further randomised
studies, in which carboplatin dosage is based on the AUC
calculation, and in which amifostine (at a dose level of
683 mg m-2 t.i.d.) is given with the first chemotherapy course
in order to avoid a possible cumulative carboplatin toxic
effect, will be needed to confirm these results.
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